Sulfasalazine is an aminosalicylate primarily used in the treatment of rheumatoid arthritis. It exerts its effects by reducing inflammatory markers, reducing neutrophil adhesion to endothelial cells, inhibiting folate metabolizing enzymes and T & B cell proliferation. It has a more rapid onset of action and prevents radiological progression. It is considered to be safe for use in pregnant women. It can be used in combination with other DMARDs and has long-term safety of over a year in the treatment of RA.